• Explore /
  • Poster
  • / Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).

Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).

Abstract Poster

Authors

null

David Hogg

Princess Margaret Cancer Centre, Toronto, ON, Canada

David Hogg , Paul B. Chapman , Mario Sznol , Christopher D. Lao , Rene Gonzalez , Gregory A. Daniels , Michael Smylie , Ragini Reiney Kudchadkar , John A. Thompson , William Howard Sharfman , Michael B. Atkins , Anna C. Pavlick , Joel Jiang , Alexandre Avila , Sheena Demelo , F. Stephen Hodi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02186249

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9522)

DOI

10.1200/JCO.2017.35.15_suppl.9522

Abstract #

9522

Poster Bd #

130

Abstract Disclosures

Similar Posters

First Author: Jeffrey S. Weber

First Author: F. Stephen Hodi

First Author: Dirk Schadendorf

First Author: Geoffrey Thomas Gibney